Information Provided By:
Fly News Breaks for June 18, 2019
CVS
Jun 18, 2019 | 08:30 EDT
Jefferies analyst Brian Tanquilut believes the "muted" reaction to CVS Health's recent articulation of its planned strategic moves and issuance of guidance thru 2022 underscore the "show-me stance" investors continue to take on the name. The analyst does not see any meaningful near-term catalysts that could drive "significant" stock upside over the next 12 months. That said, the stock's downside is "limited by a discounted valuation," Tanquilut tells investors in a research note. He keeps raised his price target for CVS Health to $58 from $57 and keeps a Hold rating on the name.